(a)

	mTOR  inhibitor	Change in GFR (mL/min/1.73 m2) after conversion					Change in serum creatinine concentration (mg/dL) after conversion		Change in CrCl (mL/min) from baseline at postconversion time point
		3 months	6 months	1 year	2 years	5 years	6 months	1 year	6 months	1 year
Levy et al. Liver Transpl. 2006; 12: 1640–8 [52]	EVR								EVR: 1, 2, and 4 mg/day versus placebo: −18.7, −36.5, and −33.2 versus −37	EVR: 1, 2, and 4 mg/day versus placebo: −20.2, −43.0, and −36.9 versus −36.9
Chinnakotla et al. Liver Transpl. 2009; 15: 1834–1842 [55]	SRL	−46.5 versus −41.0 (SRL versus TAC)		−39.5 versus −30.0 (SRL versus TAC)	−43.5 versus −31.5 (SRL versus TAC)	−38.5 versus −37.0 (SRL versus TAC)
Campsen et al. J Transplant. 2011; 2011: 913094 [54]	SRL		−2.85 versus −9.66 (CNI versus SRL, P = 0.0465)	−6.29 versus −13.32 (CNI versus SRL, P = 0.0320)
Zimmerman et al. Liver Transpl. 2008; 14: 633–8 [15]	SRL						−0.22 versus +0.61 (SRL versus CNIs, P = 0.0021)	−0.28 versus +0.35 (SRL versus CNIs, P < 0.0001)

P values are included where available.

CNI: calcineurin inhibitor; CrCl: creatinine clearance; EVR: everolimus; GFR: glomerular filtration rate; mTOR: mammalian target of rapamycin; SRL: sirolimus; TAC: tacrolimus.